LOCAL COST STUDY OF TREATMENT OF VENOUS THROMBOEMBOLISM IN TURKEY
Author(s)
Tatar M1, Senturk A2, Tuna E2, Bilginer B1, Ulus AT1, Buyuktuna N3, Hacibedel B4, Saribas G5, Poyraz MB6
1Hacettepe University, Ankara, Turkey, 2Polar Health Economics and Policy Consultancy, Ankara, Turkey, 3Bristol Myers Squibb, Istanbul, Turkey, 4Pfizer Pharmaceuticals, Istanbul, Turkey, 5Pfizer Pharmaceuticals, Department of Health Economics and Outcomes Research, Istanbul, Turkey, 6TOBB ETU University, Ankara, Turkey
OBJECTIVES: Venous thromboembolism (VTE) is a common disorder, with about 1 per 1,000 people per year in the general population.Approximately two-thirds of cases of VTE present as deep vein thrombosis (DVT), the formation of a thrombus in a deep vein, usually of the lower limbs. Around one third of VTE cases present as pulmonary embolism (PE), occurring when dislodged thrombi (from a DVT) travel to the lungs. PE can cause sudden death and those who survive an episode occasionally require intensive care, with recovery taking several weeks or months. The clinical course of DVT may also be complicated by recurrent episodes of DVT, the development of post-thrombotic syndrome (PTS), as well as chronic thromboembolic pulmonary hypertension (CTEPH). The aim of study was to estimate the cost of VTE treatment in Turkey. METHODS: The study was undertaken from the Turkish health care payer perspective. (SSI). An Excel sheet was formed to determine the healthcare resources used in treatment of VTE. VTE treatment costs were divided by anticoagulant use, monitoring INR, recurrent DVT, recurrent PE, non IC major bleeding (GIS), Intracranial bleed, CTEPH and PTS long term costs.Resource utilization data were obtained via expert clinical views and included diagnosis costs and treatment costs. Unit costs were taken from the Social Security Institution’s Health Implementation Guideline. RESULTS: According to the results of the study,cost ofanticoagulans were146,59 TL, monitoring INR costs were 90,00 TL, recurrent DVT costs were 1.972,41 TL, recurrent PE costs were 830,49 TL, non IC major bleeding (GIS) costs were 1.482,49, Intracranial bleed costs were 3.868,86 TL, CTEPH costs were 22.228,12 TL and PTS long term costs were 754,29 TL in Turkey. CONCLUSIONS: The study showed that VTE treatment poses a high treatment cost due to recurrence and OAC complications in the Turkish health care system.
Conference/Value in Health Info
2015-11, ISPOR Europe 2015, Milan, Italy
Value in Health, Vol. 18, No. 7 (November 2015)
Code
PCV87
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
Cardiovascular Disorders